Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 996 participants.
Also called NCT02594501
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 996 participants
- Sponsor
- CeloNova BioSciences, Inc.
- Registry
-
NCT02594501
-
- Other papers using this trial's data
- Long term follow up of patients treated with a polymer coated non drug-eluting stent in the COBRA-REDUCE trial
- Randomized Trial of COBRA PzF Stenting to Reduce the Duration of Triple Therapy: The COBRA-REDUCE Trial
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Denmark, France, Germany, Italy, Latvia, Switzerland
- Registry status
- Unknown status
Technical summary
Registry record NCT02594501. Randomized; no masking; primary purpose treatment. Start 2016-02-05 (registry gives no type); primary completion 2021-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
- Acronym
- COBRA-REDUCE
- Condition
- Angina, Stable
- Condition
- Angina, Unstable
- Condition
- Anticoagulants
- Intervention (Device)
- COBRA PzF
- Intervention (Device)
- Drug Eluting Stent
- Lead sponsor
- CeloNova BioSciences, Inc.
Record details
- Record id
cardio:ct-nct02594501- Content hash
6796e3a73f65ebd89ceb9934807fdeee86213ebbb1f8a6949a3ebcb4f44ef277